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Recent genetic studies have demonstrated the
importance of epidermal gap junctions with muta-
tions in four b-connexins associated with autosomal
dominant epidermal disease. One of these disorders,
erythrokeratoderma variabilis, is associated with
germline mutations in the genes encoding connexins
(Cx) Cx31 and Cx30.3. Towards understanding the
functional mechanism of Cx31 mutations in epider-
mal disease, we have developed and characterized a
polyclonal antibody raised against human Cx31.
Using this antibody to immunostain normal epider-
mis, Cx31 protein was found to be expressed predo-
minately in the stratum granulosum with a punctate
pattern of staining at the plasma membrane. In add-
ition, we used reverse transcriptase polymerase chain
reaction and, where reagents were available, immu-
nocytochemistry to investigate which other connex-
ins are expressed in the epidermis. Surprisingly, this
analysis revealed that there are at least 10 connexins
expressed with an overlapping distribution and local-
ization to distinct keratinocyte subpopulations.
These data provide additional evidence for multiple
gap junction channel types in the human epidermis.
Elucidation of this complexity of channel types with
respect to speci®c permeabilities and function of
each wildtype and mutant channel type in epidermal
biology will require further investigations. Key words:
gap junction/intercellular communication/keratoderma. J
Invest Dermatol 117:958±964, 2001
G
ap junctions are intercellular channels allowing the
passage of low molecular weight substances
(<1000 Da) such as second messengers, ions, and
nutrients between cells. In the epidermis this direct
cytoplasmic exchange of metabolites and ions is
thought to coordinate epidermal homeostasis. The importance of
gap junctions in epidermal differentiation is supported by the
discovery that mutations in gap junction proteins are the underlying
cause of several inherited skin disorders (Kelsell et al, 2001).
The major proteins of gap junctions are connexins (Cx).
Connexins are membrane proteins composed of four hydrophobic
transmembrane domains oriented such that both the N and C
termini of the molecule are cytoplasmic (Unger et al, 1999). Six
connexin molecules assemble to form a ring structure known as a
connexon. Connexons interact with similar structures in neigh-
boring cells to form functional channels. There are at least 14
different human connexin molecules differentially expressed in a
tissue- and state-speci®c manner. The contribution of different
connexin molecules to the mature gap junction is unclear but
heterotypic interactions between connexons have been demon-
strated to form functional channels (Cao et al, 1998).
There is evidence for the expression of a number of connexins in
human epidermis, including Cx26 and Cx43 (Guo et al, 1992;
Salomon et al, 1994; Lucke et al, 1999), Cx31, Cx31.1 (Richard
et al, 1998a), Cx30 (Lamartine et al, 2000), and Cx30.3 (Macari et al,
2000). Cx43 and Cx26 have been most widely studied. Cx43 is
found in both interfollicular epidermis and epidermal adnexae
whereas Cx26 is restricted to the adnexae where it shows
codistribution with Cx43 (Salomon et al, 1994). Low levels of
Cx26 have also been reported to occur in the basal cells of plantar
skin (Lucke et al, 1999). Cx43 and Cx26 are differentially expressed
during strati®cation of keratinocytes in culture (Wiszniewski et al,
2000) and Cx26 has been shown to be upregulated in keratinocytes
of psoriatic lesions (Labarthe et al, 1998; Lucke et al, 1999). Both of
these connexins are upregulated by retinoic acid (Masgrau-Peya
et al, 1997).
Several connexin gene mutations have been identi®ed as the
cause of a number of epidermal disorders. Mutations in the gene
encoding Cx26 have been found to cause syndromes of deafness
and palmoplantar keratoderma (Richard et al, 1998b; Maestrini et al,
1999; Kelsell et al, 2000). Mutations in both Cx31 and Cx30.3 give
rise to the skin disease erythrokeratoderma variabilis (EKV)
(Richard et al, 1998a; Wilgoss et al, 1999; Macari et al, 2000) and
mutations in Cx30 are the cause of Clouston's hidrotic ectodermal
dysplasia (Lamartine et al, 2000). In addition to causing skin disease,
different mutations in Cx26, Cx30, and Cx31 can result in
nonsyndromic hearing loss (Kelsell et al, 1997; Xia et al, 1998; Grifa
et al, 1999; Liu et al, 2000). In particular, mutations in Cx26 are a
major cause of recessive hereditary hearing loss (http://www.
iro.es/CX26deaf.html). Mutations in Cx31 can also give rise to a
syndrome of deafness and neuropathy (LoÂpez-Bigas et al, 2001).
Thus, different mutations in the same gene can result in a variety of
phenotypes affecting different tissues.
The most parsimonious explanation for the different phenotypic
manifestations of mutations in connexin genes is that other
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connexins are able to compensate for the mutated proteins. In
addition to the position and nature of the mutation in the connexin
molecule, the phenotype of the disease may also depend on which
other connexins are expressed in a given tissue. Evidence to support
this hypothesis comes from mouse studies in which Cx32 and Cx40
have been shown to be able to compensate, at least partially, for
Cx43 (Plum et al, 2000). Therefore to understand the contribution
of a particular connexin to gap junction function it is necessary to
characterize the expression and distribution of other connexins
within a given tissue and cell type.
A major problem with such studies is the current lack of
characterized human connexin antibodies. To start to address this
issue we have generated a new antibody to Cx31 and used this to
study Cx31 expression in normal epidermis. We have also used
reverse transcriptase polymerase chain reaction (RT-PCR) to
identify expression of other cutaneous connexins and immunocy-
tochemistry to identify and compare expression of other connexins
in the epidermis. We have identi®ed transcripts for 10 different
connexins in human skin and, from immunocytochemistry, seven
that are expressed in the epidermis with distinct but overlapping
expression.
MATERIALS AND METHODS
Tissue and keratinocyte culture Fresh normal human palm was
obtained from consenting volunteers. Interfollicular epidermis was
obtained from excess tissue derived from either breast or abdominal
reduction surgery and follicular epidermis from excess tissue derived
from face-lift surgery. Biopsies for immuno¯uorescence staining were
immediately snap-frozen in liquid nitrogen and stored at ±70°C until
needed, and those for primary keratinocyte culture were collected in
transfer medium and prepared by enzymatic dispersion (Leigh and Watt,
1994). HeLa cells were cultured in Dulbecco's modi®ed Eagle's medium
supplemented with 10% fetal bovine serum. After reaching con¯uence,
the cells were freed from the ¯asks with the addition of trypsin and
plated on dishes for transfection.
Cx31 antibody Polyclonal antibody was raised in rabbits against the
human Cx31 peptide, PDPGNNKLQASAPNLTPI (position 253±270aa:
GenBank accession number CAA06165), conjugated with bovine serum
albumin (BSA). The immunization schedule was as follows. The Cx31
peptide±BSA conjugate emulsi®ed in complete Freund's adjuvant (1:1)
was injected subcutaneously at multiple sites in two rabbits. Approval for
this study was given (MUREX project 4033). Two weeks after the ®rst
injection, a booster injection in incomplete Freund's adjuvant was given
subcutaneously. This was repeated ®ve times at 2 wk intervals, and then
rabbits were exsanguinated and the antiserum was collected. The
antiserum was af®nity-puri®ed, ®rst on a HiTrap rProtein A column,
and second on a Sephadex G-25 column (Amersham-Pharmacia Biotech,
U.K.). The procedures were performed following the manufacturer's
recommended protocol.
Immuno¯uorescence staining and confocal microscopy Frozen
tissue sections of about 6 mm thickness were cut using a cryomicrotome.
Sections were then rinsed with phosphate-buffered saline (PBS) and
incubated in PBS containing 3% rabbit or goat serum and 0.1% Triton
Table I. Antibodies used in the study
Antibody protein domain Dilution for staining Source Reference
monoclonal antimouse Cx26 C terminus 1:100 Zymed Lucke et al, 1999
polyclonal rabbit antimouse Cx30 C terminus 1:50 Zymed Nagy et al, 1999
polyclonal rabbit antihuman Cx31 C terminus 1:100 In house
monoclonal antirat Cx32 Cytoplasmic loop 1:100 Zymed Kojima et al, 1999
polyclonal rabbit antimouse Cx40 C terminus 1:50 Alpha diagnostic Harold, 2000
monoclonal antirat Cx43 near C terminus 1:100 Zymed Nagy et al, 1997
polyclonal rabbit antimouse Cx45 near C terminus 1:22 Alpha diagnostic van Veen et al, 2000
Table II. Primers for RT-PCR
Connexins Accession No. Forward primers (5¢±3¢) Reverse primers (5¢±3¢)
Annealing
temperature Fragment length (bp)
Cx26 M86849 TCTTTTCCAGAGCAAACCGC GACACGAAGATCAGCTGCAG 60 285
Cx30 HSA005585 TCAACAAACACTCCACCAGC CAATCCCACATTTCAACACC 55 477
Cx30.3 AL121988 TACCCACCTGCATCCACTGG GGTGGACGTACTTGCTGAGC 60 409
Cx31 AF052692 AATTCTCGCAGGTAGGCACG CCAGAGAGTGTGCAGCAGGT 60 495
Cx31.1 AF052693 GTGGACATATGTCTGCAGCC CTATGAGAGATGCTAGAGC 60 492
Cx32 X04325 GACAGGTTTGTACACCTTGC CGTCGCACTTGACCAGCCGC 60 499
Cx37 M96789 GTTGCTGGACCAGGTCCAGG GGATGCGCAGGCCACCATCT 62 415
Cx40 L34954 GTACACAAGCACTCGACCGT GCAGGGTGGTCAGGAAGATT 60 506
Cx43 X52947 CAATCACTTGGCGTGACTTC GTTTGGGCAACCTTGAGTTC 60 408
Cx45 U03493 GGAGCTTTCTGACTCGCCTG CGGCCATCATGCTTAGGTTT 60 487
Cx36 NM020660 GCAGCACTCCACTATGATCG CGTCGCACTTGACCAGCCGC 60 459
Figure 1. SDS-PAGE analysis for Cx31 antibody. Cx31 protein was
translated in vitro (TNT system) or in vivo (HeLa cells) as described in
Materials and Methods and subjected to SDS-PAGE: lane 1, 14C-labeled
molecular weight marker; lane 2, 35S-methionine-labeled Cx31 protein
(the image of lanes 1 and 2 was taken by autoradiography); lane 3,
unlabeled Cx31 protein translated using the TNT system; lane 4, HeLa
cell lysate transfected with pcDNA3/Cx31; lane 5, the lysate of
untransfected Hela cells. Lanes 3, 4, and 5 were transferred to
nitrocellulose membrane after electrophoresis and blotted with the Cx31
antibody.
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X-100 (Sigma, U.K.) for 30 min at room temperature. After rinsing, the
slides were incubated in a humidi®ed chamber at 37°C for 2 h with one
of the primary antibodies listed in Table I. After several rinses with PBS,
sections were incubated in the dark for 1 h at room temperature with
¯uorescein isothiocyanate (FITC) conjugated rabbit antimouse IgG or
goat antirabbit IgG (Molecular Probes, Oregon) diluted 1:100. For Cx31
staining, after incubation with primary antibody, the section was
incubated with 1:200 swine antirabbit IgG±biotin conjugate (Dako,
Denmark) for 1 h at room temperature and then incubated with 1:100
FITC±streptavidin (Dako) for 30 min. After rinsing with PBS, the
sections were mounted in mowiol reagent containing 10% mowiol D-
488 (Calbiochem, U.K.), 25% glycerol, and 2.5% 1.4-diazabicyclo[2.2.2]
octane (Sigma, U.K.) in 50 mM Tris/HCl, pH 8.5. The images of
expression and distribution of the connexin protein were recorded using
a Ziess LSM510 laser scanning confocal microscope (Carl Zeiss,
Germany) and were processed using Adobe Photoshop 5.
Cx31 construct Full-length Cx31 gene was cloned into the pcDNA3
express vector (Invitrogen, U.S.A.). PCR was carried out on wildtype
human genomic DNA using Cx31-speci®c primers incorporating ECOR
V or Xba I restriction sites (underlined in primer sequence), GCG-
GATATCACCATGGACTGGAAGACACTC (5¢±3¢) for forward
primer and GCGTCTAGATCAGATGGGGGTCAGGTT (5¢±3¢) for
reverse primer. The resulting PCR product was cloned into the ECOR
V/Xba I sites of pcDNA3.
In vitro transcription/translation of Cx31 1 mg of pcDNA3/Cx31
DNA was subjected to transcription and translation using the TNT T7
transcription/translation system (Promega, U.K.) with 35S-methionine
(Amersham-Pharmacia Biotech) or nonradioactive methionine following
the manufacturer's recommended protocol. The synthesized proteins
were then separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and detected by autoradiography or
immunoblotting.
SDS-PAGE and immunoblotting HeLa cells transfected with
pcDNA3/Cx31 were harvested and lyzed in SDS loading buffer
containing 2% SDS, 10% glycerol, 2.5% b-mercaptoethanol, a protease
inhibitor cocktail (Roche, Germany), and 50 mM dithiothreitol in
50 mM Tris/HCl, pH 6.8. The lysates were sonicated three times for 10
s with 15 s intervals and centrifuged at 12,000g for 5 min. Cell lysate and
synthesized proteins from the TNT system were separated by 12% SDS-
PAGE. After electrophoresis, the gel containing 35S-methionine-labeled
proteins was ®xed, dried, and subjected to autoradiography. The gel
containing HeLa cell lysates and nonradioactive methionine synthetic
proteins was transferred onto a nitrocellulose membrane and probed
using the af®nity-puri®ed rabbit anti-Cx31 (1:200) antibody. The blots
were further incubated with a secondary antirabbit IgG±horseradish
peroxidase conjugate (Dako), and were developed using the enhanced
chemiluminescence plus system (Amersham-Pharmacia Biotech).
Figure 2. Connexin 31 portein in the human
epidermis. The expression pattern of Cx31
protein in (a) normal human interfollicular
epidermis (scale bar: 20 mm), (b) normal palm
epidermis (scale bar: 20 mm), (c) the outer root
sheath of the hair follicle (scale bar: 20 mm) (taken
from the boxed area in (e), scale bar: 10 mm), and
(d ) sebaceous gland (scale bar: 20 mm) (taken from
the boxed area in (f ), scale bar: 10 mm).
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RT-PCR Total RNA was separated using Trizol reagent (Life
Technologies, U.K.), and mRNA was extracted and puri®ed using
oligo(dT)-cellulose (Amersham-Pharmacia Biotech). The procedures
were performed according to the manufacturer's instructions. 50 ng
mRNA was reverse transcribed to ®rst-strand cDNA by Moloney
murine leukemia virus reverse transcriptase with random hexamer primer
(Perkin Elmer, U.K.) in a 20 ml reaction mixture, and 3 ml of reverse
transcribed product was ampli®ed by PCR using the primers listed in
Table II. The PCR program was 94°C for 2 min, followed by 35 cycles
as follows: 94°C for 30 s, 55°C or 60°C or 62°C for 30 s, 72°C for
45 s, completed with a ®nal extension of 72°C for 10 min. As all paired
primers lie within a single exon (most connexins are encoded in a single
exon), a control for each RT-PCR was run using the same conditions
but without reverse transcriptase to eliminate the possibility of genomic
DNA contamination. RT-PCR products were separated on a 2% agarose
gel containing 0.5 mg per ml ethidium bromide and visualized using a
UVP transilluminator.
In situ hybridization for Cx31 The pCRII-TOPO/Cx31 DNA was
linearized with restriction enzymes Hind III (sense) and Not I
(antisense). cRNA sense and antisense probes were generated using the
DIG RNA labeling kit (Boehringer Mannheim, Germany) with DIG
labeled UTP. Frozen sections of about 10 mm thickness of human palm
were used for in situ hybridization. The procedure was as described
previously (Machesney et al, 1998). Images after in situ hybridization
were recorded using a Leica DC200 microscope (Milton Keynes, U.K.)
under the same brightness and contrast settings.
RESULTS
Characterization of Cx31 antibody For Cx31 protein
localization, a polyclonal antibody raised against a peptide
sequence corresponding to the intracellular C-terminus tail of
human Cx31 was characterized. This peptide sequence is part of
the intracellular region of the C-terminus of the protein and is
speci®c to human Cx31 based on sequence homology alignments
with all the known connexins. In addition, BlastP analysis of this
peptide sequence against the translated nucleotide GenBank
database (via http://www.ncbi.nlm.nih.gov/) did not detect
signi®cant homology with any other predicted or known peptide
sequence other than Cx31. Speci®city of the Cx31 antibody was
assessed following SDS-PAGE and immunoblotting. The results
showed that the af®nity-puri®ed Cx31 antibody recognized a single
31 kDa after Cx31 was synthesized in vitro (TNT system) or when
Figure 3. The expression pattern of connexin
proteins in normal human interfollicular
epidermis. Immuno¯uorescence staining using
connexin antibodies: (a) Cx26; (b) Cx30; (c)
Cx32; (d ) Cx40; (e) Cx43; (f ) Cx45. Scale bar:
20 mm.
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expressed in vivo (transfected HeLa cells) by pcDNA3/Cx31. The
weaker lower band may represent a dephosphorylated form of
Cx31. The 31 kDa band comigrated with the 31 kDa band of 35S-
methionine-labeled protein (Fig 1). In contrast, there was no
31 kDa band (or the weaker lower band) in the nontransfected
HeLa cells. Immunocytochemical analysis of normal palm and
interfollicular skin using this Cx31 antibody indicated that Cx31
was present in the suprabasal layer of the epidermis with higher
protein levels in the stratum granulosum than in the stratum
spinosum (Fig 2a, b). The pattern of staining was punctate and
localized to the plasma membrane presumably representing Cx31
gap junction plaques between adjoining keratinocytes. From
immunocytochemistry of hair-bearing skin, Cx31 also stained
positively in the sebaceous gland and the innermost layer of the
outer root sheath (Fig 2e, f).
Distribution of other connexins in human epidermis
(protein data) Immunocytochemical analysis using six
commercially available connexin antibodies (Cx26, Cx30, Cx32,
Cx40, Cx43, and Cx45) illustrated the distribution and
morphology of these connexin proteins in human interfollicular
epidermis (Fig 3) and palm epidermis (Fig 4). All connexin
proteins showed a punctate staining at the plasma membrane
suggesting the protein localized at gap junction plaques between
adjoining keratinocytes. Observationally, it appeared that
expression levels of connexins were higher in palm than in
interfollicular epidermis.
Cx26 in palm had a patchy distribution and was detectable in
regions of the stratum basale, rarely detectable in the stratum
spinosum, and detectable again in the stratum granulosum. Cx26 in
interfollicular epidermis was rarely detectable though there was a
strong punctate staining in sweat duct (image not shown). These
Cx26 localization data are similar to those described in previous
studies using the same monoclonal anti-Cx26 antibody (Lucke et al,
1999). In the palm, Cx30 and Cx45 were detected in the suprabasal
layers with the highest levels of protein expression in the granular
cells. They both had a similar pattern of expression in interfollicular
epidermis but the Cx30 protein expression levels were much less
than that in palms. Cx40 was present in the suprabasal layers in both
palm and skin with uniformly protein levels between granular cells
and spinous cells. A low level of Cx32 protein was detectable,
Figure 4. The expression pattern of connexin
proteins in normal palm epidermis.
Immuno¯uorescence staining using connexin
antibodies: (a) Cx26; (b) Cx30; (c) Cx32; (d )
Cx40; (e) Cx43; (f ) Cx45. Scale bar: 20 mm.
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particularly in the palm. As described previously, Cx43 was
detected in the suprabasal layers with, subjectively, the highest
protein expression levels in the granular cells (Salomon et al, 1994).
Evidence for other connexins expressed in human skin (RT-
PCR) To determine if other connexins were present in human
skin, we investigated how many of the known human connexins
were actually expressed in normal palm and interfollicular skin.
Ampli®cation of mRNA from human palm and interfollicular skin
by RT-PCR revealed that there were at least 10 connexins
expressed in interfollicular skin. In addition to the connexins
identi®ed by immunocytochemistry (Cx26, Cx30, Cx31, Cx32,
Cx40, Cx43, and Cx45), transcripts for Cx30.3, Cx31.1, and Cx37
were also found to be present (Fig 5). The smaller PCR product
generated for Cx37 represents a nonspeci®c PCR artifact. Cx36
was the only tested connexin that was negative in all skin mRNA
tested (data not shown). The lens-speci®c connexins Cx46 and
Cx50 were not tested. For Cx31 mRNA analysis, tissue in situ
hybridization of human palm skin was also performed and revealed
that Cx31 mRNA was uniformly distributed predominately in basal
keratinocytes and in the stratum spinosum (Fig 6). This contrasts
with the Cx31 protein distribution revealed by
immunocytochemistry. The difference could be due to the Cx31
protein only being translocated to the plasma membrane in the
stratum granulosum.
DISCUSSION
In this study, we have examined the expression of Cx31 in human
epidermis by immunocytochemistry, RT-PCR, and tissue in situ
hybridization. To perform the former analysis, we have character-
ized a new polyclonal antibody raised against the intracellular
region of the C terminus of the human Cx31 protein. This domain
of the protein is speci®c to human Cx31. Immunocytochemical
analysis with this antibody revealed that Cx31 was expressed
strongly in the stratum granulosum of both interfollicular and
palmoplantar epidermis with a punctate pattern of staining localized
at the plasma membrane. No Cx31 protein was detected in
cultured keratinocytes by immunocytochemistry or by immuno-
blot (data not shown). These protein expression and localization
data suggest that Cx31 has a more prominent role in gap junction
intercellular communication in later stages of keratinocyte differ-
entiation. In addition to studying mutant Cx31 in EKV lesional
epidermis and keratinocytes, this new antibody will be useful to
characterize Cx31 expression in other cell types including those
affected by speci®c dominant Cx31 mutations such as peripheral
neurons and the epithelia of the inner ear (Xia et al, 1998; LoÂpez-
Bigas et al, 2001).
Previous studies have shown that the major epidermal connexin
proteins are Cx43 and Cx26. From expression studies in rodents
(Butterweck et al, 1994) and the identi®cation of human epidermal
disease-associated connexin mutations (Richard et al, 1998a;
Lamartine et al, 2000; Macari et al, 2000), however, other
connexins such as Cx31, Cx30.3, and Cx30 must also be expressed
in the epidermis. At least 14 human connexin genes have now been
identi®ed and we have investigated their expression pro®le in
human skin. RT-PCR analysis of interfollicular and palmoplantar
skin identi®ed transcripts for 10 connexins. Immunocytochemistry
using antibodies representing epitopes for Cx31 (as discussed
previously), Cx26, Cx43, Cx32, Cx40, Cx30, and Cx45 con®rmed
that at least seven of these connexins are also expressed at the
protein level in the epidermis localizing at the plasma membrane
with a characteristic punctate pattern. Previously, it has been
reported that Cx32 and Cx40 were absent in human epidermis
(Salomon et al, 1994). In our study, however, RT-PCR and
immunocytochemistry revealed that these connexin proteins are
indeed components of the epidermis, though Cx32 is only
expressed at low levels. In rodent skin, Cx45, Cx40, Cx37,
Cx31.1, Cx31 in addition to Cx26 and Cx43 have previously been
shown to be present, suggesting there is a similar complex pattern
of connexin expression in human and rodent epidermis
(Butterweck et al, 1994; Goliger and Paul, 1994).
Mutations in four connexins have been associated with
autosomal dominant inherited epidermal disease: Cx26 and
Vohwinkel's syndrome or palmoplantar keratoderma associated
with different types of hearing impairment; Cx31/Cx30.3 and
EKV; and Cx30 and Clouston's hidrotic ectodermal dysplasia
(Richard et al, 1998a; Maestrini et al, 1999; Kelsell et al, 2000;
Lamartine et al, 2000; Macari et al, 2000). As mutations in Cx31 and
Cx30.3 underlie clinically similar forms of EKV, it is tempting to
speculate that Cx30.3 and Cx31 colocalize in the epidermis, and to
address this we are currently developing antibodies raised against
human Cx30.3. The expression pattern of Cx26 and Cx31 in
normal human epidermis re¯ects, to some degree, the extent of
epidermal disease with Cx26 expression restricted to the palmo-
plantar epidermis and Cx31 expressed in both palmoplanter and
interfollicular epidermis. As the clinical onset and severity can vary
in a patient's lifetime and between individuals harbouring the same
connexin mutation, however, other epidermal connexins must be
able to compensate for the mutant connexin protein and maintain a
``normal'' epidermal state. As recessive mutations in Cx26 and
Cx31 underlie nonsyndromic hearing loss (Kelsell et al, 1997; Liu
et al, 2000), it is likely that epidermal connexins can compensate for
Figure 6. Distribution of Cx31 mRNA in
palm. The Cx31 mRNA was detected by in situ
hybridization: (a) sense; (b) antisense. Scale bar:
10 mm.
Figure 5. Connexin mRNA expressed in human interfollicular
and palm skin. mRNA transcripts were ampli®ed from human skin
(upper image) and palm (low image) by RT-PCR. (±) indicates that the
ampli®cations in the absence of reverse transcriptase were used as
controls.
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the ``loss'' of these connexin proteins. Another issue in connexin
disease biology is that some dominant connexin mutations in the
same protein cause skin disease and others cause hearing loss or
both phenotypes.
Functional studies using the paired Xenopus oocyte assay and
mammalian cell culture systems and have shown that some
connexin mutations are processed differently (Richard et al,
1998b; White et al, 1998; Martin et al, 1999). These systems have
only assayed mutant proteins individually, however, and not with
respect to the full complement of other connexins expressed in the
affected tissue. The characterization of the connexin content of the
epidermis and developing antibodies raised against each connexin
will enable the study of mutant connexins in the cell type affected
such as keratinocytes. This will allow investigation of the effect of
mutation on keratinocyte differentiation and on other endogenous
connexins. These studies may shed light on the genotype-
phenotypes of speci®c connexin mutations.
In summary, we have shown that in the human epidermis
multiple connexin proteins are expressed in distinct keratinocyte
subpopulations but with an overlapping distribution. The question
that then arises is why there are so many. It has been demonstrated
that speci®c homomeric and heteromeric connexons form selective
channels with different af®nities for the transport of ions and
metabolites and having distinct gating properties (Goldberg et al,
1999; Niessen et al, 2000). Thus it is likely that, in the epidermis,
speci®c channel types will have distinct properties of gap junctional
intercellular communication and further studies are required to
dissect their speci®c permeabilities to ions and metabolites. It is also
plausible that not all the epidermal connexins will have a role in gap
junctional intercellular communication as there is evidence that
some connexons form hemichannels that regulate extracellular
calcium ion concentration (Quist et al, 2000) and some may
associate with speci®c tight junction proteins (Giepmans and
Moolenaar, 1998; Kojima et al, 1999).
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